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Abstract (Word count 245, MCT 250 word limit) 
HER2/ERBB2 status is used to select patients for HER2-targeted therapy. HER2/ERBB2 
amplification/overexpression of upper gastrointestinal (UGI) adenocarcinomas was determined 
locally or in two central laboratories to select patients for the TRIO-013/LOGiC trial of 
chemotherapy with or without lapatinib. Patients selected locally had central laboratory 
confirmation of HER2-amplification for inclusion in the primary efficacy population. HER2 was 
assessed with PathVysion or IQ PharmDx fluorescence in situ hybridization (FISH) and 
HercepTest immunohistochemistry assays. Associations with outcomes were retrospectively 
evaluated.  Overall, HER2 status was determined in UGI cancers from 4674 patients in a central 
laboratory for eligibility (1995 cases) and for confirmation of local HER2 results (333 cases).  Of 
1995 adenocarcinomas screened centrally, 322 (16.1%) had HER2 amplified disease with 29 
(1.5%) showing HER2 genomic heterogeneity. Men and older patients had higher rates of 
amplification. Of 545 patients accrued to the trial (gastric, 87.3%; GEJ, 8.3% and esophageal 
cancer, 4.4%) 487 patients (89%) were centrally confirmed as having HER2 amplified disease. 
Concordance between central and local HER2 testing was 83%. Concordance between 
PathVysion and IQ PharmDx FISH assays was 99% and FISH in the two central laboratories was 
95%. Lapatinib-treated Asian participants and those less than 60 years had significant 
improvement in progression-free survival (PFS), particularly among those whose cancers had 
5.01-10.0 and >10.0-fold amplification of HER2.  In conclusion, HER2 is commonly amplified 
in UGI adenocarcinomas with amplification highly correlated to overexpression, and HER2 
amplification levels correlated with PFS.  While HER2 genomic heterogeneity occurs, its 
prevalence is low.    
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Introduction   
 
The human epidermal growth factor receptor (EGFR) type 2 (HER2) gene (aka ERBB2) is 
commonly amplified(1-3) and overexpressed in adenocarcinomas of the stomach, 
gastroesophageal junction (GEJ) and esophagus and is a potential target for therapeutic 
intervention. Although the role of HER2 as a prognostic marker in gastric cancer remains an 
issue of debate, HER2 amplification/overexpression is an important therapeutic target for 
trastuzumab and is associated with significant improvements in progression-free(PFS) and 
overall survival(OS)(4).   Routine diagnostic testing is now recommended in gastric and GEJ 
adenocarcinomas based on these findings that led to approval of the drug by the U.S. Food and 
Drug Administration(FDA)(5) and European Medicines Agency (EMA).   
Here we report on assessments of HER2 status conducted for patient entry to a trial of 
lapatinib, a dual tyrosine kinase inhibitor of HER2 and EGFR, in combination with 
chemotherapy in patients with advanced HER2-positive upper gastrointestinal(UGI) 
adenocarcinomas.  The TRIO-013/LOGiC study was based on efficacy of lapatinib in HER2-
positive breast cancer patients(6-9) and activity both in vitro and in vivo with UGI cancer cell 
lines exhibiting HER2 gene amplification(10).  In addition, modest single-agent activity had been 
observed in patients with UGI cancers.  At the time this trial was initiated no anti-HER2 agent 
had demonstrated activity in a systematic study of this disease. This retrospective study of HER2 
gene amplification and overexpression in UGI adenocarcinomas was initiated to explore the 
potential roles of HER2 amplification levels and HER2 genomic heterogeneity in lapatinib 
treatment responsiveness, as measured by improved PFS or improved OS in the LOGiC clinical 
trial.   
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Materials and Methods   
TRIO-013/LOGiC clinical trial.  The TRIO-013/LOGiC clinical trial (Lapatinib 
Optimization Study in ErbB2 {HER2} Positive Gastric Cancer: A Phase III Global, Blinded 
Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib) was 
a double-blind, randomized, multi-center, phase III study (ClinicalTrials.gov: NCT00680901) of 
capecitabine and oxaliplatin (CapeOx) without or with lapatinib conducted in patients with 
metastatic HER2-positive gastric, GEJ, and esophageal adenocarcinoma between June 2008 and 
January 2012 at 186 centers in 22 countries.  The details of patient accrual, treatment, toxicities 
and outcomes are described separately(11). Here we describe HER2 testing issues and their 
associations with outcomes. The study was conducted in accordance with the current ethical 
principles outlined in the Declaration of Helsinki guidelines(12).  
HER2 Status for Enrollment in the TRIO-013/LOGiC clinical trial.  Patients enrolled in this 
trial had advanced, HER2-positive UGI adenocarcinomas as evaluated in local laboratories 
(Immunohistochemistry {IHC} 2+ and fluorescence in situ hybridization (FISH)-amplified, or 
IHC3+, or FISH-amplified) or in a central laboratory (FISH-amplified).  Patients enrolled in the 
trial with a positive HER2 local test result were required to have tumor tissue submitted to one of 
two central laboratories for assessment of HER2 gene amplification by the HER2 PathVysion 
FISH assay (Abbott Molecular, Inc., Des Plaines, Illinois) and expression by IHC (HercepTest, 
Dako Biotechnology, Carpinteria, CA) for confirmation of the local result.  Although patients 
could be enrolled to the trial based on HER2-positive status in a local laboratory, patient 
inclusion in the primary efficacy population (PEP) required HER2 gene amplification confirmed 
by a central laboratory.  The PEP was composed of all patients whose tumors were centrally 
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determined as HER2-amplified. The primary endpoint was OS in the PEP.  PFS was a secondary 
endpoint.  
Conduct of the trial.  Patients whose UGI cancers were assessed as HER2-positive by 
either IHC or in situ hybridization assay and otherwise eligible for the trial(11) were stratified 
according to history of prior adjuvant or neoadjuvant therapy and region (Asia, North America 
and rest of the world) then randomized to receive oxaliplatin (130 mg/m2 on day one) and 
capecitabine (850 mg/m2, bid, days 1-14) either with lapatinib (1250 mg daily, day 1-21) or with 
placebo (daily, day 1-21).   
Identification of PEP.  As no HER2 tests were approved for use in UGI cancers at the start 
of the trial, Translational Research In Oncology (TRIO) / Cancer International Research Group 
(CIRG) selected the PathVysion dual-color FISH assay (HER2 PathVysion FISH assay, Abbott 
Molecular, Inc.) as the primary method for assessment of HER2-amplification in patients’ 
cancers to establish a consistent standard for HER2-positivity across the trial based on previous 
approval as a companion diagnostic for breast cancer patient selection to HER2-targeted 
therapies and experience with this assay method(8, 13-18).  Formalin-fixed paraffin-embedded 
(FFPE) tissues or unstained sections were submitted to a central laboratory for assessment of 
HER2 status(Figure 1A).   
Laboratory Assessment of HER2 status.  HER2 amplification was determined by FISH, as 
described(15-17) (Supplementary Data), in one of two central laboratories, one at the University 
of Southern California (Los Angeles, California) and the other at the University Medical Center 
Hamburg-Eppendorf (Hamburg, Germany). The entire processed tissue section was routinely 
screened for focal areas of carcinoma with HER2 status that differed from the remaining tumor 
both by IHC and FISH (HER2 genomic heterogeneity). When such areas of disparate HER2 gene 
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copy number were identified they were scored separately by FISH and the tumor area estimated.  
HER2 amplification was defined as a HER2 gene-to-CEP17 ratio of 2.0 or greater, the U.S. 
FDA–approved ratio; an average HER2 gene copy number of 4.0 or greater was not required(19-
21).  Similarly for IHC, high geographic variability in HER2 immunostaining (e.g. areas of IHC 
3+ and other areas of IHC 0/1+ that are consistent with HER2 genomic heterogeneity) were 
noted and the percent of each area was estimated (see Figure 2 and Supplementary Figures S1 
and S2).   
HercepTest IHC Assay. During the conduct of this trial it became apparent, based on 
reports from ToGA trial investigators(4, 22), that there may be some controversy related to 
HER2 testing in gastric and GEJ adenocarcinomas.  Therefore, TRIO/CIRG investigators and the 
trial sponsor decided to also implement immunohistochemistry (IHC) testing for HER2 protein 
in the central laboratories. The HercepTest(Dako, Inc.), a companion diagnostic initially 
approved for breast cancer assessments and subsequently, approved for gastric and GEJ 
adenocarcinomas, was used to determine HER2 protein expression as described(15-17) and 
summarized in Supplementary Methods.  
Concordance Study. The HER2 PathVysion FISH assay was selected as the primary testing 
method for assessment of HER2 status; however, during the trial questions were raised about 
assay comparability with the HER2 IQFISH pharmDx method (Dako Corporation) which 
became FDA-approved for HER2 testing in gastric cancer for selection of patients to 
trastuzumab therapy.  In order to assess agreement rates between assay methods and agreement 
rates in the two central laboratories, a separate cohort of 488 UGI adenocarcinoma cases, 
419(86%) gastric, 43(8.8%) gastroesophageal junction(GEJ), and 26(5.3%) esophageal cancers, 
were procured from commercial providers (Asterand Bioscience, Analytical Biological Services, 
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Inc., Proteogenex, Inc., Individumed GmbH) as FFPE blocks and screened by HercepTest to 
ensure representation of all four IHC staining intensities (Figure 1B).  All IHC3+ and IHC2+ 
cases were included in the concordance study. Whereas IHC1+ and IHC 0 cases were grouped by 
primary tumor site (gastric, GEJ and esophageal) with inclusion of all GEJ and esophageal 
carcinomas, then gastric carcinomas were randomly selected.  The 159 selected cases were 
masked and sent to two central laboratories for HER2 FISH testing, masked to all information.   
Data Analyses. Statistical aspects of the LOGIC study design and statistical methods for 
analyses are summarized elsewhere(11).  Briefly, we performed a Cox proportional hazards 
model on treatment for each of the subgroups to compute a hazard ratio and 95% confidence 
interval.  Then using the unstratified log rank test, we computed p-values, as well as median 
survival times and 95% confidence intervals for both PFS and OS.  Although the analyses 
between FISH results and outcomes reported here are exploratory and hypothesis generating, the 
differences observed retrospectively in a clinical trial were still considered in our analyses as 
potentially meaningful, namely, they warrant further exploration in a subsequent study, or not.  
We chose a p-value of ≤0.05 as our threshold to suggest a marker / analysis was meaningful.  For 
concordance analyses, positive percent agreement (PPA), negative percent agreement (NPA) and 
overall percent agreement (OPA) with 95% confidence intervals were determined as 
described(23) and summarized in Supplementary Methods. 
 
Results 
HER2 Testing in the TRIO-013/LOGiC Trial.  Overall, 4674 patients were registered in the 
central database and underwent eligibility screening for the TRIO-013/LOGiC trial(Figure 1A). 
Central FISH testing was performed in 1995 patients for eligibility and 333 for confirmation of a 
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local HER2 result; one patient enrolled and deemed HER2 positive by a local laboratory did not 
have tumor tissue remaining for central confirmation of HER2 status and FISH results were not 
obtained from six additional samples(Figure 1A).  Of the 1995 carcinomas screened by a central 
laboratory for trial enrollment, 322(16.1%) had HER2 amplification(Figure 1A), 29(1.5%) of 
which showed HER2 genomic heterogeneity(Figure 2). The adenocarcinomas with genomic 
heterogeneity represent 9% of identified HER2-amplified cases primarily screened in the central 
laboratories. An additional 33 cases with HER2 genomic heterogeneity were identified among 
those screened in local laboratories and confirmed in a central laboratory. Demographic data for 
these patients demonstrates a higher frequency of disease among men and shows that men and 
older patients have higher rates of HER2 gene amplification (Table 1).   
In patients whose cancers were centrally assessed, either for primary assessment or 
confirmation of local laboratory results, HER2 status by both FISH and IHC is known for 1250 
with 457/547(83.5%) amplified cases IHC2+ or IHC3+ and 680/703(96.7%) non-amplified cases 
either IHC1+ or IHC0 (Table 2). The overall concordance rate between FISH and IHC results for 
HER2 status was 91% (95% confidence interval{CI}: 89.2%, 92.4%).  In our dataset, there were 
no cases that were IHC3+/FISH-negative. The majority (84%) of IHC2+ cases were HER2 
amplified, while relatively few IHC0(n=33, 6%) or IHC1+(n=57, 26%) cancers were HER2 
amplified(Table 2).  The distribution across the various IHC immunostaining categories 
progressively transitions from predominantly IHC0 (515/703, 73.3%) without amplification 
(FISH ratio <2.0), to a more even distribution (IHC0{18%}, IHC1+{28%}, IHC2+{35%}, 
IHC3+{19%}) with low-level amplification (FISH ratio of 2.0-5.0) to progressively higher 
distributions of stronger IHC staining (IHC0{2%}, IHC1+{6%}, IHC2+{24%}, IHC3+{67%}) 
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for FISH ratios >5.0-10.0 and the highest distribution (IHC3+{91%}) for FISH ratios >10.0 
(Table 2).    
Of 333 patients with trial enrollment based on local laboratory testing, 332 had tumor tissue 
available for subsequent re-assessment in a central laboratory (Supplementary Table S1). 
Concordance between central and local HER2 testing was 84.4% (275/326, Figure 1A). Since 
samples were not required for re-evaluation in the central laboratory for patients not enrolled to 
the trial, overall concordance in this population could not be assessed.  
The agreement rate between local and central laboratory HER2 testing was dependent on 
the HER2 testing method used in the local laboratory and concordance varied accordingly.  
Among the 332 cancers evaluated both locally and centrally, 259 cases were tested in local 
laboratories by ISH alone, 33 by ISH and IHC, and 40 by IHC alone.  Among the 292 cases 
tested locally by ISH, the central laboratory determined the HER2 gene amplification status in 
286 of the cases. HER2 amplified status was confirmed for 250; however, 36 were assessed as 
not amplified for an ISH concordance rate of 87% (95% CI: 83.1%, 90.8%)(Supplementary 
Table S2).  Seven cases had been evaluated by CISH in local laboratories and five of the cases 
were confirmed as amplified by central laboratory FISH. Agreement between local laboratory 
and central laboratory for HER2 IHC assays was even less (58%) (Supplemental Supplementary 
Table S3), although the number of cases analyzed was limited and different assays may have 
been used locally (n=73). 
Concordance Study for Different HER2 FISH assay methods between the two Central 
Laboratories.  Before accrual to the LOGiC trial was complete, the ToGA trial was completed 
and the FDA, subsequently, approved two companion diagnostic assays, the Dako HercepTest 
IHC assay (October, 2010) and the Dako HER2 IQFISH pharmDx FISH assay (February, 2013) 
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for selection of gastric and GEJ cancer patients to trastuzumab plus chemotherapy(4).  Therefore, 
we performed a concordance study to demonstrate agreement between the PathVysion HER2 
FISH assay and the Dako HER2 IQFISH pharmDx HER2 assay (Figure 1B and Supplementary 
Results and Supplementary Tables S4 and S5).  UGI adenocarcinomas from 488 patients who 
were not enrolled in the TRIO-013/LOGiC trial were used for the concordance studies (Figure 
1B).  In order to ensure the full spectrum of HER2 expression was more evenly represented in 
the concordance comparison rather than a predominance of HER2 low-expression, not-amplified 
cases, the tumors were initially processed and scored by IHC with the selection of 159 cases for 
further analysis by FISH.  The central laboratory was blinded to the prior IHC status during 
FISH analyses performed in the central laboratories.  The initial IHC results from all 488 UGI 
cancers showed highly variable immunostaining in 17 cases (3.5%) that was considered 
consistent with potential HER2 genomic heterogeneity (Supplementary Figures S1 and S2).  The 
central masking/randomization center included 14 of these IHC-variable cases that had sufficient 
tumor for inclusion in the concordance study thus increasing the rate of potential “HER2 
heterogeneity” from 3.5%(17/488) to 8.8%(14/159).  Of the 159 cases selected for inclusion in 
the concordance study: 31 exhibited HER2 staining indicative of IHC3+, 20 IHC2+, 55 IHC1+ 
and 53 IHC0(Figure 1B). 
Overall concordance between LOGiC central laboratories for 151 cases successfully tested 
by PathVysion HER2 FISH assay in both laboratories was 94.7% (95%CI:89.9%, 97.3%) with 
93.8% PPA (95%CI:83.2%, 97.9%) and 95.1% NPA (95%CI:89.1%, 97.9%)(Supplementary 
Table S5).  Discordance between the two central laboratories was primarily related to differences 
in scoring of 14 samples with highly variable HER2 immunostaining, consistent with HER2 
genomic heterogeneity (Supplementary Results, Supplementary Figures S1 and S2).   
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Summary of clinical outcomes in the TRIO-013/LOGiC trial.  In total, among the 545 
patients accrued to the trial, 487 patients had central-laboratory-confirmed HER2 amplified 
disease to comprise the primary efficacy population (PEP); while 51 had HER2 non-amplified 
disease and HER2 amplification status was not determined in seven patients (Table 3 and Figure 
1A).   
Among the 487 patients with HER2-amplified cancers in the PEP, 424(87.1%) had gastric, 
43(8.8%) GEJ and 20(4.1%) esophageal cancers.  In the PEP 297 had cancers that were HER2 
IHC3+ (61%), 108 were IHC2+ (22%), 54 were IHC1+ (11%), 27 were IHC0 (6%), and one was 
IHC unknown.  As reported separately in detail(11), the LOGiC trial did not meet its primary 
end-point of a significant improvement in OS among those patients randomized to receive 
chemotherapy with lapatinib (HR=0.91 {95%CI: 0.73, 1.12}, p-value=0.35); however, a 
significant improvement in PFS was observed (HR=0.82 {95%CI: 0.68, 1.00}, p-value=0.038).  
Subset analyses demonstrated meaningful improvements in both PFS and OS for selected subsets 
of patients, such as those accrued in Asian countries and those patients less than 60 years of age 
at trial enrollment (Table 3 and Supplementary Table S6).  Among Asian participants and those 
less than 60 years of age we observed greater PFS related to higher levels of HER2 gene 
amplification(Table 3). In the overall trial population (>10.0-fold) as well as among the Asian 
population (5.01-10.0 and >10.0-fold) and in the population less than 60 years of age the hazard 
ratio for PFS became more pronounced only at higher levels of HER2 gene amplification (>5.0-
10.0 and >10.0 fold)(Table 3).  HER2 ratio was not associated with OS in the overall population 
or in the sub-populations analyzed for PFS (Table 3)(p value >0.05), with the exception of Asian 
participants whose cancers had 5.01-10.0 HER2 gene amplification levels. 
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Among the 81 cases included in the trial with HER2 gene amplification by FISH with only 
IHC0/1+ for HER2 protein, hazard ratios for PFS were (HR=1.12, p-value=0.65) and OS 
(HR=0.91, p-value = 0.71).  In contrast, those patients whose HER2-amplified UGI cancers were 
also IHC2+/3+ had greater improvement in PFS (HR=0.76, {95%CI: 0.62, 0.94}, p-
value=0.0096) but not OS (HR=0.86 {95%CI: 0.68, 1.09}, p-value=0.21).  Among the 148 
participants from Asian countries with HER2-amplified/IHC2+/3+ UGI adenocarcinoma, PFS 
(HR=0.59; p-value = 0.0020) and OS (HR=0.60, p-value=0.0108) were greatly improved by the 
addition of lapatinib to chemotherapy.  These results were highly intriguing and will be proposed 
for further prospective assessments in subsequent studies.  
 
Discussion 
Gastric cancer remains the third leading cause of cancer-related mortality in the world(24). 
Treatment typically involves gastric resection; however, surgery alone is generally only curative 
for patients with early-stage disease.  For patients with advanced resectable disease, survival 
rates remain poor but are improved by chemotherapy and possibly radiotherapy(25-27). 
HER2 amplification/overexpression as a prognostic marker.  The majority of gastric cancer 
studies do not show an association of HER2 status with clinical outcomes in the absence of 
chemotherapy and/or radiation therapy(28-37); however, studies of patients treated with 
chemotherapy and/or radiation therapy demonstrate a survival advantage for patients whose 
gastric cancers lack HER2 gene amplification/overexpression(32, 38-41). An additional large 
study of patients with adenocarcinomas of the gastric cardia, gastroesophageal junction and 
esophagus treated by surgical resection (1980-1997) showed no difference in either disease-
specific survival or OS among patients whose cancers had HER2 gene amplification(42). The 
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potential role of HER2 as a predictive marker of responsiveness to chemotherapy and radiation 
therapy is supported by a retrospective analysis of HER2 gene amplification and overexpression 
in gastric cancers from patients in the INT-0116/SWOG9008 phase III gastric cancer clinical 
trial comparing surgery alone with surgery and chemotherapy (5-fluorouracil)/radiation 
therapy(13).  Patients whose gastric cancers were HER2-negative and were treated with 
chemoradiation therapy had a longer disease-free and overall survival than similar patients 
treated with gastrectomy alone.  In contrast, no benefit from chemotherapy and radiation therapy 
was observed among the subset of patients whose gastric cancers had HER2 
amplification/overexpression(13).   
HER2 amplification/overexpression as a target for therapy. HER2 
amplification/overexpression is an important therapeutic target for trastuzumab in metastatic 
gastric and gastroesophageal cancer(4), as it is in metastatic breast cancer(9, 18, 43).  Both the 
Trastuzumab for Gastric Cancer (ToGA) and LOGiC trials were initiated because of medical 
need in gastric/gastroesophageal/esophageal carcinoma, a high HER2 positivity rate and an 
already established toxicity profile in breast cancer patients. The ToGA clinical trial assessed 
efficacy and safety of trastuzumab added to capecitabine or fluorouracil and cisplatin 
chemotherapy for first-line treatment of advanced gastric or gastro-esophageal junction cancers 
with overexpression of HER2(4).  Among patients assigned to chemotherapy with trastuzumab 
in the ToGA trial, median OS was 13.8 months (95% CI 12–16) compared with 11.1 months for 
those assigned to chemotherapy alone (HR 0∙74; 95%CI: 0∙60–0∙91; p=0∙0046).  In the LOGiC 
trial the median OS was 12.2 months (95%CI: 10.6, 14.2) for patients assigned to capecitabine 
and oxaliplatin chemotherapy with lapatinib compared with 10.5 months (95%CI: 9.0, 11.3) for 
patients assigned to chemotherapy and placebo (HR: 0.91 {95%CI: 0.73, 1.12}; p=NS)(11).  
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Although differences in survival among the overall LOGiC trial population were not observed, 
Asian patients and patients under 60 years of age did show noticeable improvements in OS(44).  
However, we did not find any systematic difference in HER2 status by either 
immunohistochemistry or FISH among these subgroups that could account for the differences in 
outcome.   
HER2 testing in UGI cancers.  Routine diagnostic HER2 testing is recommended in gastric 
and GEJ adenocarcinomas based on findings from the ToGA trial that led to regulatory approval 
of trastuzumab for this indication in 2010.  We found a high concordance rate for HER2 gene 
amplification status determined with two different FISH assays (99% agreement) and between 
two different central laboratories when the same FISH assay is used (95% agreement), even 
though the comparison samples were enriched for cases with HER2 genomic heterogeneity 
(8.8%). Agreement between local laboratory and central laboratory for HER2 FISH assays was 
only 87%. Agreement between local laboratory and central laboratory for HER2 IHC assays was 
less (58%)(Supplementary Table S3); however, the number of cases available for this analysis 
was quite limited.  Overall agreement between HER2 IHC and FISH assays in the central 
laboratory was approximately 90%, 91% in the LOGiC clinical trial cases (n=1250) and 88% in 
the concordance cohort cases (n =155).  The discrepancies identified for HER2 status determined 
by IHC compared to FISH, as well as disagreements between local and central laboratory testing, 
have the potential to inappropriately select some patients for HER2 targeted therapy as well as 
the potential to inappropriately deny other patients such treatment.  Our findings suggest this is 
of particular concern when IHC is used as the primary test, as addressed elsewhere in detail(20).   
There has been some concern that UGI endoscopic biopsies may not provide sufficient 
tissue for adequate identification of all cancers with this alteration.  Although we did not have 
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both endoscopic biopsy samples and resection specimens from the same patients for a direct 
case-by-case comparison, our HER2 amplification rates among patients with endoscopic biopsy 
specimens (18.3%) compared to patients who had surgical resection specimens (15.0%) suggests 
that endoscopic biopsies are likely to be representative of the HER2 amplification status 
(Supplementary Results and Supplementary Table S7).   
HER2 genomic heterogeneity.  HER2 genomic heterogeneity was observed overall in 
approximately 1%-2% of the UGI adenocarcinomas in this study (Table 1, Figure 2 and 
Supplementary Figures S1 and S2).  The rate did not vary significantly by patient age, gender, 
country, or anatomical site.  Although the total number of these cases identified by the central 
laboratory was modest (n=62), 51 of the cases were identified in patients who were subsequently 
randomly assigned to study treatment, 24 to the lapatinib treatment arm and 27 to the control arm, 
no significant differences were observed in PFS or OS.  It should be noted that our definition(15) 
of HER2 genomic heterogeneity differs from the definition used in CAP guidelines(45).   
The definition of HER2 genomic heterogeneity used in the LOGiC trial was the same as 
used for trials of breast cancer screened in the same two TRIO/BCIRG central laboratories(16) 
for the BCIRG-005(46), BCIRG-006(8) and BCIRG-007(47) trials.  We consider HER2 genomic 
heterogeneity to exist when at least one geographically defined area of contiguous tumor cells 
are identified within a cancer that differs from the remaining tumor cells by HER2 amplification 
status (i.e. HER2 amplified versus HER2 not amplified).  This differs from the definition 
established by the CAP guidelines for breast cancer(45).  The CAP criteria do not distinguish or 
require a geographically defined area but simply that the scores of 20 or more cells have at least 
5% of scored cells with a HER2-to-CEP17 ratio that is >2.2 and less than 50% of the tumor cells 
have such a ratio.  The guidelines state “HER2 genetic heterogeneity (GH) exists if there are 
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more than 5% but less than 50% of infiltrating tumor cells with a ratio higher than 2.2.” We also 
differ from the guidelines in our approach to scoring HER2 heterogeneity.  According to the 
guidelines, “if 20 cells are counted and at least one cell is identified with a HER2/CEP17 signal 
ratio higher than 2.2, this specimen contains GH. Likewise, if 60 cells are examined and 3 or 
more cells have a ratio higher than 2.2, HER2 GH is present.” Using this definition leads to 
substantially higher rates of HER2 heterogeneity by FISH ranging from 14% to 26% in breast 
cancers(48, 49). However, use of the same definition in gastric cardia, gastroesophageal junction 
and esophagus adenocarcinomas demonstrated only 20 of 675(2.9%) have HER2 genetic 
heterogeneity(42).  These studies contrast with our previously reported lower rates (0.5% and 
1.1%) in breast cancer(15, 16, 21) and similarly low rate for UGI cancers reported here.  The 
CAP definition(45) may lead to the inclusion of a number of cases that do not contain any HER2 
gene amplification even in a portion of the tumor.  For example, we would consider some of the 
results generated by the CAP definition to reflect inclusion of (scattered) cancer cells in which a 
proportion of the cells (exceeding 5%) are in G2- or M-phase of the cell cycle where DNA has 
been duplicated leading to doubling of the number of copies of HER2 gene but without a 
doubling of chromosome 17 centrosomes since the centromeres remain fused until late 
metaphase. These (scattered) individual cells have a HER2 FISH ratio greater than 2.0, are not 
amplified, but contribute to “genetic heterogeneity” by the CAP definition.  These tumor cells 
are, likely, simply proliferating (Campeau A and Press MF, unpublished data).  
As illustrated (Figure 2, Supplementary Figures S1 and S2), we have required that the 
differing geographic tumor areas be scored separately and that one area of contiguous tumor cells 
have an overall FISH ratio less than 2.0 and the other area have a ratio greater than 2.0 with 
distinctly aggregated or clustered HER2 gene signals in the amplified cancer cells. Accordingly, 
on June 25, 2018. © 2016 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 3, 2016; DOI: 10.1158/1535-7163.MCT-15-0887 
18 
 
62 cases with HER2 genomic heterogeneity were identified in this study with 51 accrued to the 
trial. Only two of these cases had genomic heterogeneity in a subpopulation of tumor cells 
representing less than 5% of the total area of the tumor.  A limitation of our estimates of HER2 
genomic heterogeneity is that we seldom had more than a single tissue block from the primary 
carcinoma from which to make these evaluations.  Therefore, our frequencies should be 
considered from this perspective.   
Association of Lapatinib responsiveness with HER2 amplification level.  In breast cancer 
clinical trials of lapatinib we have found a relatively uniform hazard ratio for PFS that was 
independent of HER2 amplification level in HER2-amplified breast cancer patients(15). Only 
patients whose metastatic disease lacked HER2 amplification (HER2 FISH ratio <2.0) showed no 
improvement in PFS with lapatinib treatment (HR = 1.09, 95%CI:0.86-1.37; n=390), while 
patients whose metastatic disease with low-level (2.0-5.5-fold) amplification (HR=0.48, 95%CI: 
0.28-0.83; n=82), moderate (5.5-7.6-fold)(HR=0.35, 95%CI: 0.18-0.69; n=89), high (7.6-10.1-
fold) (HR=0.58, 95%CI: 0.33-1.05; n=87) or very high-level (>10.1-fold) amplification 
(HR=0.42, 95%CI: 0.24-0.74; n=88) levels all showed improved PFS associated with lapatinib 
treatment.   
In contrast, this trial of lapatinib in UGI cancer patients with advanced disease showed an 
association between lapatinib treatment and improved PFS only at higher levels of HER2 
amplification.  In the entire trial population of UGI cancer patients, those without amplification 
(FISH ratios <2.0; HR=0.89, 95%CI: 0.50-1.59; n=51), with low-level amplification (FISH ratios 
2.0-5.0; HR=0.90, 95%CI: 0.63-1.29; n=140) and with moderate-level amplification (FISH ratios 
5.01-10.0; HR=0.92, 95%CI: 0.66-1.28; n=171) showed no significant improvement in PFS, 
while UGI patients whose metastatic cancers had high-level amplification (FISH ratios >10.0; 
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HR=0.64, 95%CI: 0.47-0.88; n=176) showed significant improvements in PFS with lapatinib 
treatment.  Similarly, in the trial population of Asian UGI cancer patients, those whose cancers 
lacked HER2 amplification (FISH ratios <2.0; HR=0.99, 95%CI: 0.37-2.63; n=21) as well as 
those whose cancers had low-level amplification (FISH ratios 2.0-5.0; HR=0.77, 95%CI: 0.44-
1.37; n=56) showed no significant PFS improvement, while those whose cancers had moderate-
level amplification (FISH ratios 5.01-10.0; HR=0.62, 95%CI: 0.66-1.02; n=84) and high-level 
amplification (FISH ratios >10.0; HR=0.59, 95%CI: 0.33-1.04; n=53) showed significant 
improvements in PFS with lapatinib treatment.  Similar observations were made among UGI 
cancer patients less than 60 years of age at trial entry where only patients whose 
adenocarcinomas with low-level HER2 amplification did not show improvements in PFS with 
lapatinib treatment.   
Other investigators have reported similar associations between improved clinical outcomes 
and moderate or high levels of HER2 gene amplification in gastric cancer patients treated with 
trastuzumab(50, 51).  In a cohort of 90 patients Gomez-Martin et al. report a mean HER2/CEP17 
ratio of 4.7 as the optimal cutoff value discriminating sensitive and refractory patients (P = 
0.005); a ratio of 4.45 as the optimal cutoff for survival >12 months (P = 0.005), and a ratio of 
5.15 as the optimal cut-off for survival >16 months (P = 0.004)(50).  Although there were only 
66 patients in the Ock et al study with HER2 gene amplification status determined by FISH, the 
conclusions were similar(51).  Neither of these studies have a control, untreated group to confirm 
that patients with a HER2/CEP17 ratio less than 4.7 lack significant improvement in outcomes; 
however, patients whose cancers have ratios more than approximately 5 show improved 
outcomes compared to those whose cancers have lower levels of gene amplification. These 
findings are consistent with our own findings of greater benefit among patients whose cancers 
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have higher levels of amplification (ratio 5.0-10 and >10).  
The LOGiC trial did not show a significant association with OS(44), while ToGA did(4). 
LOGiC demonstrated a significant association with PFS but not with the primary end-point of 
OS. We consider this to be potentially influenced by several issues including 1.) sample size and 
its influence on statistical power, 2.) differential drug efficacy between lapatinib and trastuzumab 
and 3.) treatment compliance.  Design of the original LOGiC trial was probably slightly under-
powered (n=545 in LOGiC compared to 594 in ToGA), since LOGiC was originally based on 
PFS as the initial primary end-point, which was later changed to an OS primary end-point. After 
exclusion of patients whose disease was HER2-not-amplified, the PEP was limited to 487 
participants.  LOGiC might have benefited from enrollment of additional participants to gain 
statistical power for an association with OS.  Second, the differential in median OS favored the 
ToGA trial (ToGA: 13.8 versus 11.1 months; compared to LOGiC: 12.2 versus 10.5 months).  
However, it is unknown what role treatment compliance may have played in the clinical 
outcomes. LOGiC may have had a lower rate of compliance with experimental drug treatment.  
In contrast to trastuzumab with the requirement for intravenous administration, lapatinib, an oral 
medication, was self-administrated by most participants.  This introduces the potential for 
reduced compliance in the lapatinib treatment arm, especially among patients who may have 
experienced gastrointestinal side-effects.  These issues are compounded by our observations, 
reported here, that HER2 gene amplification levels may impact clinical outcomes. 
  Finally, we have not analyzed the potential for other concurrent alterations to effect 
treatment resistance.  For example, co-amplification of HER2 and MET is relatively common in 
esophago-gastric carcinomas(1, 52) and is associated with lack of treatment response to either 
MET kinase inhibitor (crizotinib) or HER2 inhibitor (trastuzumab) treatment but is associated with 
therapeutic response to combined treatment in patients with advanced esophago-gastric carcinomas(52).  
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A comprehensive assessment of genetic alterations in cancers from patients in the LOGiC trial would 
potentially provide important information about co-occurring alterations associated with HER2 
amplification and lack of treatment response.   
In summary, HER2 status determined by IHC and FISH was highly correlated in UGI 
cancers.  The prevalence of HER2 gene amplification was slightly higher in UGI cancers from 
men compared to women and was also higher among older patients.  HER2 genomic 
heterogeneity was relatively infrequent, approximately 1.6% overall.  The level of HER2 
amplification was also correlated with responsiveness to lapatinib treatment in UGI cancer 
patients.     
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Table 1.  Demographic information for 1995* patients whose cancers were assessed initially 
for HER2 status in the central laboratories for eligibility. 
Characteristic  HER2-
amplified 
HER2-not-
amplified 
HER2 Genomic 
Heterogeneity 
Totals P-
value**
Age (years)      
 
 
0.0038 
<39    (n = 92) 11 (11.9%) 80 (87%) 1 (1.1%) 92 
40-49  (n = 224) 29 (12.9%) 192 (85.8%) 3 (1.3%) 224 
50-59  (n = 529) 75 (14.2%) 449 (84.9%) 5 (0.9%) 529 
60-69  (n = 585) 105 (17.9%) 471 (80.6%) 9 (1.5%) 585 
70-79  (n = 320) 63 (19.7%) 246 (76.9%) 11 (3.4%) 320 
>80     (n = 27) 9 (33%) 18 (67.0%) 0 (0%) 27 
NA (n = 30) 1 29 0 30 
Total:    293 (16.2%) 1485 (82.2%) 29 (1.6%) 1807 
Gender        
Male  (n = 1207)   211 (17.5%) 974 (80.7%) 22 (1.8%) 1207  
0.0262 Female (n = 592) 82 (13.9%) 503 (85%) 7 (1.1%) 592 
NA (n=8) 0 8 0 8 
Total:    293 (16.2%) 1485 (82.2%) 29 (1.6%) 1807 
Country of Origin       
Brazil  41 (18.1%) 177 (78.0%) 9 (3.9%) 227  
Canada  8 (13.6%) 50 (84.7%) 1 (1.7%) 59  
Chile  22 (16.2%) 113 (83.1%) 1 (0.7%) 136  
Estonia  8 (14.3%) 48 (85.7%) 0 56  
Hong Kong  4 (22.2%) 14 (77.8%) 0 18  
Hungary    9 (13.6%) 56 (84.8) 1 (1.5) 66  
Israel   5 (13.2%) 33 (86.8%) 0 38  
Italy   23 (20.7%) 87 (78.4%) 1 (0.9%) 111  
Korea 2 (18.2%) 9 (81.8%) 0 11  
Mexico   4 (9.5%) 37 (88.1%) 1 (2.4%)  42  
Netherlands  4 (28.6%) 7 (50%) 3 (21.4%) 14  
Peru  4 (21.1%) 14 (73.7%) 1 (5.3%) 19  
Poland   52 (17.1%) 250 (82.2%) 2 (0.7%) 304  
Russia   29 (20.6%) 111 (78.7%) 1 (0.7%) 141  
Taiwan  0 1 0 1  
Thailand   1 (4.5%) 19 (86.4%) 2 (9.1%) 22  
Turkey  3 (14.3%) 18 (85.7%) 0 21  
United States  11 (23.4%) 35 (74.5%) 1 (2.1%) 47  
Ukraine  62 (13.1%) 406 (85.7%) 6 (1.2%) 474  
Totals:  n = 1807     1807  
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*Of 1995 cases centrally assessed for HER2 status, a FISH result was not available for analysis 
in188 of the cases.  **P-value was determined using Chi-sqare statistical test.  It should also be 
noted that many Asian sites used a local laboratory, e.g. in China, and provided tissue sections in 
the central laboratory only for confirmation of their status (primary efficacy population) after 
accrual to the trial (see Figure 1A). NA, not available.   
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Table 2.  TRIO-013/LOGiC Clinical Trial: Comparison of HER2 testing by FISH and IHC 
in two central laboratories. 
  Herceptest IHC score  
  IHC 0 
n  
IHC 1+  
n  
IHC 2+  
n  
IHC 3+  
n  
Totals 
PathVysion  
FISH assay 
HER2 not ampl 515 (94%) 165 (74.3%) 23 (16%) 0 703 
HER2 amplif* 33 (6%) 57 (25.7%) 121 (84%) 336 (100%) 547 
 Totals  548 222 144 336 1250 
       
  Herceptest IHC score  
PathVysion  
FISH assay 
FISH Ratios IHC 0 IHC 1+ IHC 2+ IHC 3+ Totals 
 <2.0, n (%) 515 (73%) 164 (23%) 24 (3%) 0 (0%) 703 
 2.0-5.0, n (%) 29 (18%) 45 (28%) 57 (35%) 31 (19%) 162 
 >5.0-10.0, n 
(%) 
4 (2%)  12 (6%)  45 (24%) 124 (67%) 185 
 >10.0, n (%) 0 (0%) 1 (<1%) 18 (9%) 181 (91%)  200 
  548 222 144 336 1250 
       
Of the 547 HER2 amplified UGI adenocarcinomas 90 (16.5%) had only IHC 0 or 1+ 
immunostaining for HER2 protein.   
Overall agreement between FISH and IHC results for HER2 status was 91% (1,137/1250)(95% 
confidence interval: 89.2%, 92.4%).  Other investigators have reported lower concordance 
rates between IHC and FISH, especially in the IHC 2+ group where less than 40% have 
been HER2 amplified by FISH, in esophageal / GE junction or gastric adenocarcinomas(3, 53).    
*For the 1250 cases with results summarized here HER2 genomic heterogeneity was identified in 
69 cases (4.1%) as follows by IHC group:     
Among IHC 0 there were 5 cases (0.9%) showing HER2 genomic heterogeneity.   
Among IHC 1+ there were 4 cases (1.8%) showing HER2 genomic heterogeneity.  
Among IHC 2+ there were 13 cases (9%) showing HER2 genomic heterogeneity.  
Among IHC 3+ there were 39 cases (11.6%) showing HER2 genomic heterogeneity.  
All 61 cases were tabulated as “HER2 amplified”; IHC was not available for one case with 
HER2 genomic heterogeneity demonstrated with FISH.   
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Table 3.   Correlation of PFS and OS with Responsiveness to Lapatinib in the TRIO-013 Trial for 
Central-Laboratory-Determined HER2 Gene Amplification Status#. 
All Trial Participants 
HER2 Status Number* PFS,  
HR (95% CI) 
PFS, Non-
stratified log-
rank, P-value 
OS, HR (95% CI) OS, Non-
stratified log-
rank, P-value 
    Negative  51 0.88 (0.48, 1.59) 0.6628 1.02 (0.54,1.92)    0.9617
 Positive (PEP) 487 0.81 (0.67, 0.99)  0.0350 0.88 (0.71, 1.09)    0.2319
FISH Ratios Number PFS, HR (95% CI) P-value OS, HR (95% CI) OS,  P-value 
     <2.0 51 0.89 (0.49, 1.61) 0.6868 1.04  (0.55, 1.20)   0.9172
     2.0-5.0 140 0.89 (0.62, 1.28) 0.5439 0.94 (0.64, 1.39)   0.7559
     5.01-10.0 171 0.92 (0.66, 1.28) 0.6124 0.89 (0.62, 1.30)   0.5556
     >10.0  176 0.62 (0.45, 0.86) 0.0033 0.86  (0.61, 1.21)   0.3742
 538*     
Asian Trial Participants 
HER2 Status Number HR (95% CI) P-value OS, HR (95% CI) OS,  P-value 
    Negative  21 1.00 (0.37, 2.70) 0.9794 1.33 (0.47,3.72)  0.5995
    Positive  193 0.66 (0.49, 0.90) 0.0080 0.68 (0.48, 0.96)  0.0261
FISH Ratios Number HR (95% CI) P-value OS, HR (95% CI) OS,  P-value 
     <2.0 21 1.00 (0.37, 2.70) 0.9794 1.33 (0.47, 3.72)   0.5995
     2.0-5.0 56 0.77 (0.44, 1.35) 0.3616 0.81 (0.43, 1.52)   0.5149
     5.01-10.0 84 0.62 (0.38, 1.01) 0.0511 0.56 (0.33, 0.97)   0.0375
     >10.0  53 0.57 (0.32, 1.00) 0.0479 0.77  (0.42,1.44)   0.4191
Total  214     
Trial Participants <60 years of age 
HER2 Status Number HR (95% CI) P-value OS, HR (95% CI) OS,  P-value 
    Negative  28 0.43 (0.18, 1.01) 0.0494 0.49 (0.20,1.22)  0.1210
    Positive  236 0.57 (0.44, 0.76) <0.0001 0.69 (0.51, 0.93)  0.0141
FISH Ratios Number HR(95% CI) P-value OS, HR (95% CI) OS,  P-value 
     <2.0 28 0.43 (0.18, 1.02) 0.0494 0.51 (0.20,1.26)   0.1381
     2.0-5.0 64 0.73 (0.43, 1.24) 0.2436 0.67 (0.37,1.18)   0.1626
     5.01-10.0 81 0.57 (0.35, 0.93) 0.0224 0.59 (0.34,1.02)   0.0566
     >10.0  91 0.42 (0.26, 0.68) 0.0003 0.81 (0.51,1.30)   0.3844
Total  264     
#Findings for the primary endpoint overall survival (OS) are also reported elsewhere (Hecht et al, JCO 34(5): 
443-51, 2016);findings for progression-free survival (PFS) are reported here.  *The HER2 FISH status 
was not confirmed for 7 patients enrolled in the trial (see Figure 1A).  **Analyses for participants from 
the rest of the world and participants >60 years of age are included in Supplementary Table S6.   
HR, hazard ratio; PEP, primary efficacy population; ITTP, intent to treat population.   
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Figure Legends 
 
Figure 1.  Schematic diagrams illustrating disposition of TRIO-013/LOGiC and UGI Cancer 
Concordance Cohort.  (A.) HER2 testing in the TRIO-013/LOGiC trial.  Patients’ gastric, 
GE junction or esophageal adenocarcinomas were evaluated by FISH assay for HER2 
status primarily either in a central laboratory (N = 1,995) or initially in a local laboratory 
(N = 2,678) followed by central laboratory re-evaluation of those cancers considered to be 
HER2-positive in the local laboratory (N = 333) for HER2 gene amplification status.  (B.) 
Specimen selection process for the concordance study in the central laboratories of HER2 
testing by FISH to ensure representation of GEJ and esophageal adenocarcinomas.  The 
UGI Cancer Concordance Cohort was composed of 488 UGI adenocarcinomas initially 
screened by the HER2 HercepTest to identify subgroups with strong (IHC 3+), moderate 
(IHC 2+), weak (IHC 1+) and absent (IHC 0) HER2 immunostaining. Adenocarcinomas 
originating from all three anatomical sites (esophagus, gastro-esophageal junction and 
stomach) are represented in each IHC immunostaining category (see Supplementary Table 
S4). 1One case was excluded as no tumor tissue was identified; sufficient variability in 
HER2 immunostaining was noted in 17 cases to suggest the possibility of “HER2 genomic 
heterogeneity”.  
 
Figure 2. HER2 genomic heterogeneity.  (A.) Low power photomicrograph of a gastric 
carcinoma with highly variable HER2 immunostaining that demonstrates 
geographically distinguishable regions of high (IHC 3+) and low (IHC 0) 
immunohistochemical staining.  Two regions, one with high (IHC 3+)(left box) and 
one with low (IHC 0)(right box) levels of HER2 immunostaining, are identified. 
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Original magnification: 40x.  (B. and C.) The two boxed areas from A are illustrated at 
higher magnification, one (B) showing HER2 overexpression (IHC 3+) and the other 
(C) showing low HER2 expression (IHC 0). Original magnification: 400x.  (D. and E.) 
Fluorescence in situ hybridization (FISH) of HER2 gene copies (red) and chromosome 
17 centromeres (green) of the same two regions showing HER2 gene amplification (D) 
in the region with IHC 3+ immunostaining and a LACK of HER2 gene amplification 
(E) in the region with IHC 0 immunostaining. Original magnification: 1000x.  TRIO-
013/LOGiC case number 595.   
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